España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Vertex Pharmaceuticals
VRTX
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$461.68
23.28
5.31%
At close: -
$463.58
1.90
0.41%
After Hours: 7:56 PM EDT
Get Report
Comment
Q4 2024 Earnings in 9 days from now on Mon Feb 10th, after the market close
Vertex Pharmaceuticals (VRTX) Forecast
News
Earnings
Vertex Pharmaceuticals (VRTX) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock
Vertex Pharmaceuticals Stock (NASDAQ: VRTX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, January 31, 2025
FDA Approves First Non-Opioid Pain Pill, As Medical Marijuana Remains A Proven Alternative For Relief
Maureen Meehan
Vertex Pharmaceuticals Shares Are Up Today: What's Going On?
Vaishali Prayag
Cantor Fitzgerald Reiterates Overweight on Ve...
Benzinga Newsdesk
Charter Communications Posts Upbeat Earnings, Joins Atlassian, SkyWest, Eastman Chemical, AbbVie And Other Big Stocks Moving Higher On Friday
Avi Kapoor
Scotiabank Maintains Sector Perform on Vertex...
Benzinga Newsdesk
HC Wainwright & Co. Maintains Buy on Vertex P...
Benzinga Newsdesk
Vertex Pharmaceuticals shares are trading hig...
Benzinga Newsdesk
Needham Reiterates Hold on Vertex Pharmaceuti...
Benzinga Newsdesk
Reported Earlier, Vertex Secures FDA Approval...
Benzinga Newsdesk
Vertex Secures Reimbursement Agreement For CA...
Benzinga Newsdesk
Thursday, January 30, 2025
This Everest Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Avi Kapoor
Vertex Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (21 Ratings)
Benzinga Insights
Wells Fargo Downgrades Vertex Pharmaceuticals...
Benzinga Newsdesk
Monday, January 27, 2025
Piper Sandler Maintains Overweight on Vertex ...
Benzinga Newsdesk
Friday, January 24, 2025
Cantor Fitzgerald Reiterates Overweight on Ve...
Benzinga Newsdesk
Monday, January 20, 2025
8 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
Thursday, January 16, 2025
HHS Challenges Vertex Over Fertility Services Program Tied To Casgevy Gene Therapy, Says Company Is 'Grasping at Straws'
Vandana Singh
Wednesday, January 15, 2025
How Is The Market Feeling About Vertex Pharmaceuticals?
Benzinga Insights
Tuesday, January 14, 2025
Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
Benzinga Insights
Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials
Vandana Singh
Monday, January 13, 2025
Reported Earlier, Vertex Unveils Comprehensiv...
Benzinga Newsdesk
Friday, January 10, 2025
Forecasting The Future: 23 Analyst Projections For Vertex Pharmaceuticals
Benzinga Insights
Wells Fargo Maintains Overweight on Vertex Ph...
Benzinga Newsdesk
Pfizer Is 'Too Low To Sell,' Jim Cramer Says: Recommends Nvidia For Robotics Exposure
Avi Kapoor
Vertex And Zai Lab Announce Strategic Agreeme...
Benzinga Newsdesk
Tuesday, January 07, 2025
Vertex Grapples With Bearish Chart As Death Cross Emerges
Surbhi Jain
If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today
Benzinga Insights
Orna Therapeutics Enters Three-year Strategic...
Benzinga Newsdesk
Thursday, December 26, 2024
10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights
Monday, December 23, 2024
Vertex Pharmaceuticals: Alyftrek Is An 'Accretive Opportunity' On Top- And Bottom-Lines, Says Bullish Analyst
Priya Nigam
Microsoft To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Monday
Avi Kapoor
Truist Securities Maintains Buy on Vertex Pha...
Benzinga Newsdesk
Scotiabank Maintains Sector Perform on Vertex...
Benzinga Newsdesk
JP Morgan Maintains Overweight on Vertex Phar...
Benzinga Newsdesk
Sunday, December 22, 2024
Novo Nordisk, Super Micro Computer And Arm Are Among Top Large Cap Losers Last Week (December 16-20): Are The Others In Your Portfolio?
Lekha Gupta
Friday, December 20, 2024
Vertex Pharmaceuticals Establishes Wholesale ...
Benzinga Newsdesk
Vertex Announces U.S. FDA Approval For TRIKAF...
Benzinga Newsdesk
Barclays Maintains Equal-Weight on Vertex Pha...
Benzinga Newsdesk
BMO Capital Maintains Outperform on Vertex Ph...
Benzinga Newsdesk
Needham Reiterates Hold on Vertex Pharmaceuti...
Benzinga Newsdesk
HC Wainwright & Co. Maintains Buy on Vertex P...
Benzinga Newsdesk
Thursday, December 19, 2024
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights
Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data?
Vandana Singh
B of A Securities Maintains Buy on Vertex Pha...
Benzinga Newsdesk
Vertex Pharmaceuticals shares are trading low...
Benzinga Newsdesk
Vertex Pharmaceuticals Announced Results From...
Benzinga Newsdesk
Wednesday, December 18, 2024
Check Out What Whales Are Doing With VRTX
Benzinga Insights
Monday, December 16, 2024
Tesla To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Monday
Avi Kapoor
Stifel Maintains Hold on Vertex Pharmaceutica...
Benzinga Newsdesk
Friday, December 13, 2024
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Benzinga Insights
Show More